Syndax Pharmaceuticals Inc. (SNDX) Drops 7.54% Despite Strong Q1 Earnings

Syndax Pharmaceuticals Inc. (SNDX) shares plummeted 7.54% intraday, marking the lowest level since March 2020, with a cumulative decline of 18.56% over the past three days.

The strategy of buying SNDX shares after they reached a recent low and holding for 1 week yielded moderate returns over the past 5 years. The annualized return was 18.62%, slightly underperforming the market by 3.66 percentage points. With a final value of $233.10 for a $100 initial investment, the strategy showed the importance of capturing short-term rebounds in volatile stocks like SNDX.

Syndax Pharmaceuticals reported a strong financial performance in the first quarter of 2025, driven by significant revenue from new product launches and strategic initiatives. This robust performance has likely bolstered investor confidence in the company's growth prospects.

The company's recent launches of REVUFORGE and Nyktymbo have been particularly noteworthy. These new products have addressed challenges in penetrating new markets, indicating a potential for sustained growth. The successful introduction of these products has likely contributed to the positive investor sentiment, despite the recent stock price decline.

Syndax also announced multiple data presentations at the European Hematology Association (EHA) 2025 conference. These presentations showcased clinical data for Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr), which could drive greater physician interest and potentially affect the stock price. The positive clinical data presented at the conference has likely reinforced investor confidence in the company's pipeline and future prospects.